Porownywarka

Retatrutide vs Cagrilintide side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

RetatrutideCagrilintide

Udostępnij porównanie peptydów

Wlasciwosc	Retatrutide	Cagrilintide
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	LY3437943, Triple G	AM833, NN9838, CagriSema (combination)
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Source-reported Phase 3 TRIUMPH-1 pivotal trial update (May 2026): 28.3 % mean weight loss at 80 week with 12 mg, and 45 % of patients lost 30 % or more. It calls this the largest Phase 3 obesity-drug loss result and expects an NDA submission late 2026–Q1 2027. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Weight loss, metabolic syndrome, liver fat reduction	Weight loss, appetite control, combination therapy
Jak dziala	Retatrutide is described as an agonist at GIP, GLP-1, and glucagon receptors. The source links GLP-1 signaling to lower appetite and delayed stomach emptying, GIP to insulin response and nutrient handling by fat tissue, and glucagon receptor activity to hepatic energy expenditure and fat burning. It emphasizes that the individual contribution of each receptor in humans is still uncertain.	Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.
Typowe dawkowanie	4-12 mg weekly · Once weekly, same day each week	2.4 mg weekly · Once weekly
Dawkowanie z badań	0.5mg weekly (starting) · Long-term use expected · Subcutaneous injection weekly	2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly
Typowy czas trwania	Long-term use expected	Long-term / chronic use expected
Podanie	Subcutaneous injection weekly	Subcutaneous injection once weekly
Timing	Morning, same day each week With or without food	Any consistent time weekly With or without food
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Nausea (dose-related) (Reported as dose-related.) Diarrhea (The source says individual responses can vary with dose, duration, and personal health factors.) Vomiting +6 więcej Constipation Heart rate increases Hypersensitivity reactions Dysesthesia - skin sensitivity/tingling (~21% at highest dose, TRIUMPH-4 data) (The reported rate refers to the highest dose in TRIUMPH-4 data.) Pancreatitis (rare) (Listed by the source as rare.) Currently in Phase 3 trials (This is a trial-status statement included in the source side-effect list, not an adverse effect.)	Nausea (Reported as common and usually temporary in the source.) Vomiting (Listed among reported gastrointestinal effects.) Diarrhea (Listed among reported gastrointestinal effects.) +8 więcej Constipation (Listed among reported gastrointestinal effects.) Abdominal pain (Reported in the source as a gastrointestinal adverse effect.) Injection site reactions (Reported in the source without additional severity detail.) Decreased appetite (Reported in the source; clinical relevance depends on study context.) Headache (Reported in the source without additional severity detail.) Dyspepsia (Reported in the source as a gastrointestinal symptom.) Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.) Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)
Podsumowanie researchu	According to the source summary, Jastreboff and colleagues reported a 2023 NEJM Phase 2 randomized trial involving 338 adults with obesity but no type 2 diabetes. The 48 week trial reported a mean reduction close to 24 percent at 12 mg, with no clear plateau by that endpoint. It also reports that a large majority of participants with baseline prediabetes had normal blood sugar at follow-up. Nausea, vomiting, and diarrhea predominated and were described as dose-dependent. The summary says larger, longer Phase 3 work was intended to examine durability and safety.	The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.
Referencje	Źródło Źródło +1 więcej Źródło	Źródło Źródło +3 więcej Źródło Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Retatrutide

Cagrilintide

Kategoria

Redukcja masy

Znany tez jako

LY3437943, Triple G

AM833, NN9838, CagriSema (combination)

Zatwierdzony przez FDA

Nie

Status kliniczny

Source-reported Phase 3 TRIUMPH-1 pivotal trial update (May 2026): 28.3 % mean weight loss at 80 week with 12 mg, and 45 % of patients lost 30 % or more. It calls this the largest Phase 3 obesity-drug loss result and expects an NDA submission late 2026–Q1 2027.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Weight loss, metabolic syndrome, liver fat reduction

Weight loss, appetite control, combination therapy

Jak dziala

Retatrutide is described as an agonist at GIP, GLP-1, and glucagon receptors. The source links GLP-1 signaling to lower appetite and delayed stomach emptying, GIP to insulin response and nutrient handling by fat tissue, and glucagon receptor activity to hepatic energy expenditure and fat burning. It emphasizes that the individual contribution of each receptor in humans is still uncertain.

Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.

Typowe dawkowanie

4-12 mg weekly · Once weekly, same day each week

2.4 mg weekly · Once weekly

Dawkowanie z badań

0.5mg weekly (starting) · Long-term use expected · Subcutaneous injection weekly

2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly

Typowy czas trwania

Long-term use expected

Long-term / chronic use expected

Podanie

Subcutaneous injection weekly

Subcutaneous injection once weekly

Timing

Morning, same day each week

With or without food

Any consistent time weekly

With or without food

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Nausea (dose-related) (Reported as dose-related.)
Diarrhea (The source says individual responses can vary with dose, duration, and personal health factors.)
Vomiting

+6 więcej

Constipation
Heart rate increases
Hypersensitivity reactions
Dysesthesia - skin sensitivity/tingling (~21% at highest dose, TRIUMPH-4 data) (The reported rate refers to the highest dose in TRIUMPH-4 data.)
Pancreatitis (rare) (Listed by the source as rare.)
Currently in Phase 3 trials (This is a trial-status statement included in the source side-effect list, not an adverse effect.)

Nausea (Reported as common and usually temporary in the source.)
Vomiting (Listed among reported gastrointestinal effects.)
Diarrhea (Listed among reported gastrointestinal effects.)

+8 więcej

Constipation (Listed among reported gastrointestinal effects.)
Abdominal pain (Reported in the source as a gastrointestinal adverse effect.)
Injection site reactions (Reported in the source without additional severity detail.)
Decreased appetite (Reported in the source; clinical relevance depends on study context.)
Headache (Reported in the source without additional severity detail.)
Dyspepsia (Reported in the source as a gastrointestinal symptom.)
Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.)
Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)

Podsumowanie researchu

According to the source summary, Jastreboff and colleagues reported a 2023 NEJM Phase 2 randomized trial involving 338 adults with obesity but no type 2 diabetes. The 48 week trial reported a mean reduction close to 24 percent at 12 mg, with no clear plateau by that endpoint. It also reports that a large majority of participants with baseline prediabetes had normal blood sugar at follow-up. Nausea, vomiting, and diarrhea predominated and were described as dose-dependent. The summary says larger, longer Phase 3 work was intended to examine durability and safety.

The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.

Referencje

+1 więcej

+3 więcej

Pełny profil